ulating Levels of the Innate and Humoral Immune R ulators CD 14 and CD 23 Are Associated with Adult Glioma

Downlo rgy history has been consistently inversely associated with glioma risk. Two serologic markers, soluble (sCD23) and soluble CD14 (sCD14), are part of the innate and adaptive humoral immune systems and late allergic responses in opposite directions, with sCD23 enhancing and sCD14 blunting inflammatory ses. We measured sCD23 and sCD14 in serum from blood that was drawn at a single time point from lioma patients postdiagnosis and 736 healthy controls. Glioma was strongly associated with high sCD14 st versus lowest quartile odds ratio (OR), 3.94; 95% confidence interval (95% CI), 2.98–5.21] and low (lowest versus highest quartile OR, 2.5; 95% CI, 1.89–3.23). Results were consistent across glioma gic types and grades, but were strongest for glioblastoma. Whereas temozolomide treatment was not ated with either sCD14 or sCD23 levels among cases, those taking dexamethasone had somewhat lower levels than those not taking dexamethasone. However, sCD23 was associated with case status regarddexamethasone treatment. These results augment the long-observed association between allergies and less of glioma and support a role for the innate and adaptive humoral functions of the immune system, in particular immunoregulatory proteins, in gliomagenesis. Cancer Res; 70(19); 7534–42. ©2010 AACR.